Welcome to our dedicated page for Enanta Pharmaceuticals news (Ticker: ENTA), a resource for investors and traders seeking the latest updates and insights on Enanta Pharmaceuticals stock.
Enanta Pharmaceuticals (ENTA) news coverage tracks developments from this clinical-stage biotechnology company specializing in small molecule drug discovery for viral infections and liver diseases. Based in Watertown, Massachusetts, Enanta's news flow reflects its position as a research-focused biotech with an active clinical pipeline and strategic pharmaceutical partnerships.
Enanta's news typically centers on clinical trial milestones, including Phase 1, Phase 2, and Phase 3 study results for drug candidates targeting conditions such as respiratory syncytial virus and hepatitis C. Trial readouts and FDA regulatory updates represent key news catalysts for the company, as clinical data directly impacts the company's pipeline value and partnership potential.
Partnership announcements and collaboration updates form another important news category. Enanta's relationship with AbbVie for HCV treatments generates ongoing news regarding royalty arrangements and product developments. New collaborations, licensing agreements, and milestone achievements under existing partnerships frequently drive company announcements.
Quarterly and annual financial results provide regular updates on the company's cash position, R&D spending, and royalty revenue. For clinical-stage biotechs like Enanta, cash runway and burn rate metrics receive particular investor attention, as these companies typically operate at a loss while advancing drug candidates through development.
Scientific presentations at medical conferences such as IDWeek, ESCMID, and hepatology meetings offer detailed clinical and preclinical data. Patent filings and intellectual property developments, including litigation involving drug patents, also generate company news. Capital market activities including stock offerings and financing arrangements round out the news flow for this NASDAQ-listed biotech.
Enanta Pharmaceuticals (NASDAQ:ENTA) reported its fiscal Q1 2021 results, highlighting a revenue decline to $31.7 million from $52.6 million due to lower HCV sales. R&D expenses increased to $36.7 million, and net loss expanded to $8.3 million, or $0.41 per share. Key pipeline advancements include ongoing Phase 1b trials for HBV drugs EDP-514 and EDP-721, and the Phase 2b study for RSV drug EDP-938. The company expects preliminary data from its HBV trials in Q2 2021 and aims to identify two clinical candidates in respiratory virology this year.
Enanta Pharmaceuticals (NASDAQ:ENTA) will report its fiscal Q1 results on February 8, 2021, after market close. The company's management will host a conference call at 4:30 p.m. ET to discuss the results and provide updates on its R&D pipeline, targeting viral infections and liver diseases. Enanta’s research focuses on diseases like respiratory syncytial virus, hepatitis B, and non-alcoholic steatohepatitis, with funding derived from royalties from its collaboration with AbbVie for hepatitis C virus treatments.
Enanta Pharmaceuticals (NASDAQ: ENTA) announced the appointment of Brendan Luu as Senior Vice President of Business Development, enhancing its leadership team. With over 20 years of experience in the pharmaceutical sector, Luu previously held significant roles at Merck KGaA, focusing on business development strategies. This transition comes as Enanta prepares for a catalyst-rich year, particularly in advancing its pipeline targeting viral infections and liver diseases, including promising candidates for RSV and hepatitis B.
Enanta Pharmaceuticals (NASDAQ:ENTA) announced a pipeline update at the 39th Annual J.P. Morgan Healthcare Conference, scheduled for January 12, 2021. CEO Jay R. Luly highlighted the launch of EDP-721, a promising oral hepatitis B candidate, and advancements in respiratory syncytial virus (RSV) programs, including an RSV-L inhibitor initiative. Five clinical trials were initiated in 2020, with key data expected from ongoing studies in NASH and HBV in 2021. Enanta aims to achieve a functional cure for HBV and address significant respiratory diseases.
Enanta Pharmaceuticals (NASDAQ:ENTA) has appointed Dr. John P. DeVincenzo as Vice President of Translational Virology. Dr. DeVincenzo, an expert in respiratory viral diseases with over 30 years of experience, will lead Enanta's clinical development programs for respiratory antivirals. His expertise, particularly in respiratory syncytial virus (RSV), is expected to significantly advance the company’s efforts in developing treatments for RSV and other respiratory infections. Enanta’s clinical program includes ongoing trials for EDP-938, which recently showed positive Phase 2a results.
Enanta Pharmaceuticals (NASDAQ:ENTA) announced that Dr. Jay R. Luly, President and CEO, will present at the 39th Annual J.P. Morgan Healthcare Conference on January 12, 2021, at 8:20 a.m. ET. The presentation will highlight updates on Enanta's research and development programs for 2021, followed by a Q&A session. A live audio webcast will be available on Enanta's website, with a replay archived for 30 days. Enanta focuses on developing small molecule drugs for viral infections and liver diseases, with current research targeting RSV, HBV, NASH, and COVID-19.
Enanta Pharmaceuticals (NASDAQ:ENTA) has appointed Dr. Tara L. Kieffer as Senior Vice President of New Product Strategy and Development. She brings over 20 years of experience, notably from Vertex Pharmaceuticals, where she held key roles in drug discovery and business development. This strategic hire aims to accelerate Enanta's efforts in advancing its pipeline for viral infections and liver diseases. With multiple data readouts expected in 2021, Dr. Kieffer's expertise is anticipated to bolster Enanta's initiatives towards developing new treatments.
Enanta Pharmaceuticals (NASDAQ:ENTA) reported financial results for its fiscal fourth quarter and year ending September 30, 2020, revealing a total revenue of $23.6 million for Q4, down from $51.3 million in the same period in 2019. Full-year revenue also declined to $122.5 million from $205.2 million.
The company incurred a net loss of $29.3 million in Q4, attributed to decreased HCV royalties and a non-cash tax valuation charge of $18.3 million. Enanta's cash reserves increased to $419 million. Looking ahead, the R&D expenses for fiscal 2021 are expected between $145 million and $165 million.
Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA) announced key participation in upcoming conferences. CEO Jay R. Luly will engage in a Fireside Chat at the Evercore ISI 3rd Annual Virtual HealthCONx Conference on December 1, 2020, at 9:15 a.m. ET. Additionally, he will take part in One-on-One Meetings during the Piper Sandler 32nd Annual Virtual Healthcare Conference on December 2, 2020, with a Fireside Chat available from November 25. Enanta focuses on developing small molecule drugs for viral infections and liver diseases, funded by royalties from its collaboration with AbbVie.
Enanta Pharmaceuticals (NASDAQ:ENTA) announced plans to report its financial results for the fiscal fourth quarter and year ended September 30, 2020, on November 23, 2020, after market close. A conference call will be held at 4:30 p.m. ET on the same day to discuss the results and provide updates on its business, including research and development efforts in viral infections and liver diseases. Enanta's research is funded by royalties from its collaboration with AbbVie, notably for its hepatitis C drug, Glecaprevir.
FAQ
What is the current stock price of Enanta Pharmaceuticals (ENTA)?
What is the market cap of Enanta Pharmaceuticals (ENTA)?
